-
公开(公告)号：US07803399B2
公开(公告)日：2010-09-28
申请号：US11396743
申请日：2006-04-03
Applicant: David A. Cheresh , John Hood , Mark Bednarski
Inventor： David A. Cheresh , John Hood , Mark Bednarski
CPC classification number: B82Y5/00 , A61K47/6911 , A61K48/00
Abstract: αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist.
Abstract translation: αv＆bgr; 3整合素受体靶向脂质体包含阳离子两亲物如阳离子脂质，中性脂质和靶向脂质。 靶向脂质包括非肽αv＆bgr 3整合素拮抗剂。
-
12.发明申请Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies 有权使用抗血管生成和免疫疗法的组合治疗肿瘤和转移的方法公开(公告)号：US20090060864A1
公开(公告)日：2009-03-05
申请号：US12148629
申请日：2008-04-21
Applicant: Holger N. Lode , Ralph A. Reisfeld , David A. Cheresh , Stephen D. Gillies
Inventor： Holger N. Lode , Ralph A. Reisfeld , David A. Cheresh , Stephen D. Gillies
IPC: A61K38/19 , A61K38/21 , A61K38/20 , A61K39/395 , A61P35/04
CPC classification number: C07K7/64 , A61K38/00 , A61K38/19 , A61K38/2013 , A61K39/395 , A61K45/06 , A61K47/6813 , A61K2300/00
Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
Abstract translation: 本发明提供了治疗哺乳动物肿瘤和肿瘤转移的方法，包括向需要治疗的哺乳动物施用治疗量足以抑制血管生成的拮抗剂与治疗量的抗肿瘤免疫治疗剂（例如 抗肿瘤抗原抗体/细胞因子融合蛋白，其具有足以引发细胞因子特异性生物反应的细胞因子和重组免疫球蛋白多肽链。
-
13.发明授权Methods of inhibiting angiogenesis to treat cancer with alphavbeta3-specific antibodies 失效抑制血管发生的方法，用alphavbeta3特异性抗体治疗癌症公开(公告)号：US07482007B2
公开(公告)日：2009-01-27
申请号：US10892745
申请日：2004-07-15
Applicant: Peter C. Brooks , David A. Cheresh
Inventor： Peter C. Brooks , David A. Cheresh
IPC: A61K39/395 , C07K16/28
CPC classification number: C07K14/78 , A61K38/00 , A61K2039/505 , C07K14/70557 , C07K16/2848 , C07K16/30
Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
Abstract translation: 本发明描述了使用玻连蛋白α-角蛋白3拮抗剂抑制组织中血管生成的方法，特别是用于抑制发炎组织和肿瘤组织中的血管生成以及使用含有阿尔巴博3拮抗剂的治疗组合物的转移。
-
14.发明授权Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody 失效用抗alphavbeta3单克隆抗体抑制疾病状态的血管发生公开(公告)号：US06887473B1
公开(公告)日：2005-05-03
申请号：US09081522
申请日：1998-05-19
Applicant: Peter Brooks , David A. Cheresh
Inventor： Peter Brooks , David A. Cheresh
IPC: A61K39/00 , C12N15/02 , A61K38/00 , A61K39/395 , A61K45/00 , A61P27/02 , A61P29/00 , A61P35/00 , C07K14/705 , C07K14/78 , C07K16/28 , C07K16/30 , C12P21/08
CPC classification number: C07K14/78 , A61K38/00 , A61K2039/505 , C07K14/70557 , C07K16/2848 , C07K16/30
Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
Abstract translation: 本发明描述了使用玻连蛋白α3β3拮抗剂抑制组织中血管生成的方法，特别是用于抑制发炎组织和肿瘤组织和转移中的血管生成，其使用包含 α3β3拮抗剂。
-
公开(公告)号：US5766591A
公开(公告)日：1998-06-16
申请号：US366665
申请日：1994-12-30
Applicant: Peter Brooks , David A. Cheresh
Inventor： Peter Brooks , David A. Cheresh
IPC: A61K39/00 , C12N15/02 , A61K38/00 , A61K39/395 , A61K45/00 , A61P27/02 , A61P29/00 , A61P35/00 , C07K14/705 , C07K14/78 , C07K16/28 , C07K16/30 , C12P21/08 , C07K7/00 , C07K14/745
CPC classification number: C07K14/78 , C07K14/70557 , C07K16/2848 , C07K16/30 , A61K2039/505 , A61K38/00
Abstract: The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin .alpha..sub.v .beta..sub.3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing .alpha..sub.v .beta..sub.3 antagonists.
Abstract translation: 本发明描述了使用玻连蛋白αvβ3拮抗剂抑制组织中血管生成的方法，特别是使用含有αvβ3拮抗剂的治疗组合物，特别是用于抑制发炎组织和肿瘤组织和转移中的血管生成。
-
Patent Agency Ranking
公开(公告)号：US20080175840A1
公开(公告)日：2008-07-24
申请号：US11980211
申请日：2007-10-30
Applicant: Peter Brooks , David A. Cheresh
Inventor： Peter Brooks , David A. Cheresh
IPC: A61K39/395 , A61P9/00
CPC classification number: C07K14/78 , A61K38/00 , A61K2039/505 , C07K14/70557 , C07K16/2848 , C07K16/30
Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
Abstract translation: 本发明描述了使用玻连蛋白α3β3拮抗剂抑制组织中血管生成的方法，特别是用于抑制发炎组织和肿瘤组织和转移中的血管生成，其使用包含 α3β3拮抗剂。
-
公开(公告)号：US07125849B2
公开(公告)日：2006-10-24
申请号：US10341815
申请日：2003-01-14
Applicant: David A. Cheresh , John Hood , Martin A. Schwartz , William B. Kiosses
Inventor： David A. Cheresh , John Hood , Martin A. Schwartz , William B. Kiosses
Abstract: Angiogenesis inhibitors and methods of use thereof are disclosed. The inhibitors are substantially pure oligopeptides consisting essentially of 7–20 amino acid residues and comprising a proline-rich sequence of five amino acid residues PPXPP, SEQ ID NO: 1, wherein X is an amino acid residue selected from the group consisting of alanine, glycine, serine, threonine, valine, leucine and methionine. In a preferred embodiment, the proline-rich polypeptide is covalently bound to a transport molecule such as a Tat-derived transport polypeptide.
Abstract translation: 公开了血管发生抑制剂及其使用方法。 抑制剂是基本上由7-20个氨基酸残基组成的基本上纯的寡肽，包含富含5个氨基酸残基PPXPP，SEQ ID NO：1的富含脯氨酸的序列，其中X是选自丙氨酸， 甘氨酸，丝氨酸，苏氨酸，缬氨酸，亮氨酸和甲硫氨酸。 在优选的实施方案中，富含脯氨酸的多肽与转运分子如Tat衍生的转运多肽共价结合。
-
18.发明授权Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies 有权使用抗血管生成和免疫疗法的组合治疗肿瘤和转移的方法公开(公告)号：US07115261B1
公开(公告)日：2006-10-03
申请号：US09502732
申请日：2000-02-11
Applicant: Holger N. Lode , Ralph A. Reisfeld , David A. Cheresh , Stephen D. Gillies
Inventor： Holger N. Lode , Ralph A. Reisfeld , David A. Cheresh , Stephen D. Gillies
IPC: A61K38/00 , A61K39/395 , A61K38/19
CPC classification number: C07K7/64 , A61K38/00 , A61K38/19 , A61K38/2013 , A61K39/395 , A61K45/06 , A61K47/6813 , A61K2300/00
Abstract: The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
Abstract translation: 本发明教导了用于治疗哺乳动物的肿瘤和肿瘤转移的方法，其包括向需要治疗的哺乳动物施用治疗量的足以抑制血管发生的拮抗剂与治疗量的抗肿瘤免疫治疗剂（例如 抗肿瘤抗原抗体/细胞因子融合蛋白，其具有足以引发细胞因子特异性生物反应的细胞因子和重组免疫球蛋白多肽链。
-
19.发明授权Methods and compositions useful for inhibition of αvβ5mediated angiogenesis 有权用于抑制alphavbeta5介导的血管发生的方法和组合物公开(公告)号：US07053041B1
公开(公告)日：2006-05-30
申请号：US09194552
申请日：1997-05-30
Applicant: Peter C. Brooks , David A. Cheresh , Martin Friedlander
Inventor： Peter C. Brooks , David A. Cheresh , Martin Friedlander
CPC classification number: A61K38/57 , A61K2039/505 , C07K16/2839 , C07K16/2848 , C07K2317/76
Abstract: The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin αvβ5 antagonists. The αvβ5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of αvβ5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing αvβ5 antagonists.
Abstract translation: 本发明描述了使用玻连蛋白α5β5拮抗剂抑制组织中血管生成的方法。 α-β5介导的血管发生与包括血管内皮生长因子，转化生长因子-α和表皮生长因子在内的细胞因子的暴露相关。 使用含有αV的治疗组合物，在血管内皮细胞新生血管疾病，肿瘤生长和炎性病症中，对α5β5介导的血管生成的抑制是特别优选的 5β拮抗剂。
-
公开(公告)号：US07025987B2
公开(公告)日：2006-04-11
申请号：US10158761
申请日：2002-05-30
Applicant: David A. Cheresh , John Hood , Mark Bednarski
Inventor： David A. Cheresh , John Hood , Mark Bednarski
CPC classification number: B82Y5/00 , A61K47/6911 , A61K48/00
Abstract: αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist.
Abstract translation: 整合素受体靶向脂质体包含阳离子两亲物如阳离子脂质，中性脂质和靶向脂质。 靶向脂质包括非肽α3β3整联蛋白拮抗剂。
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.037 seconds)
